



NEONATAL




LINEZOLID

This document should be read in conjunction with this [DISCLAIMER](#)

Highly Restricted: Requires Microbiologist approval before commencing

Presentation	Infusion: 600mg/300mL = 2mg/mL Oral suspension: 100mg/5mL									
Classification	Oxazolidinone antibacterial that inhibits bacterial protein synthesis.									
Indication	For infections due to Gram positive multi-resistant organisms including MRSA and VRE which are: <ul style="list-style-type: none"> refractory to conventional antibiotics such as vancomycin and; recommended by a Clinical Microbiologist or Infectious Diseases Physician. 									
Dose	<p>IV or Oral:</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Dose</th> <th>Frequency</th> </tr> </thead> <tbody> <tr> <td>Preterm and < 1 week of age</td> <td>10mg/kg/dose</td> <td>Every 12 hours</td> </tr> <tr> <td>Term or > 1 week of age</td> <td>10mg/kg/dose</td> <td>Every 8 hours</td> </tr> </tbody> </table>	Age	Dose	Frequency	Preterm and < 1 week of age	10mg/kg/dose	Every 12 hours	Term or > 1 week of age	10mg/kg/dose	Every 8 hours
Age	Dose	Frequency								
Preterm and < 1 week of age	10mg/kg/dose	Every 12 hours								
Term or > 1 week of age	10mg/kg/dose	Every 8 hours								
Monitoring	Full blood counts and liver function tests must be performed weekly. Refer for Specialist consultation if there are signs of myelosuppression.									
Preparation	<p>IV infusion: Use undiluted</p> <p>Oral suspension: Add 123mL of Water for Irrigation to the bottles in 2 parts and shake well. A uniform suspension should be formed.</p>									
Administration	<p>IV Infusion: Infuse over 30 to 120 minutes</p> <p>Oral suspension: May be given at any time with regard to feeds</p>									

Adverse Reactions	<p>Common: Diarrhoea</p> <p>Infrequent: Elevated transaminases, Rash</p> <p>Rare: Thrombocytopaenia, anaemia, leucopaenia, pancytopaenia, optic neuropathy may develop in patients treated for longer than 28 days</p>
Storage	<p>IV Infusion:</p> <ul style="list-style-type: none"> • Store at room temperature • Protect from freezing • Keep in external wrapping until prior to its use • Discard IV bag immediately after use <p>Oral suspension:</p> <ul style="list-style-type: none"> • Store at room temperature before and after reconstitution • Discard after 3 weeks.
Notes	IV Infusion may exhibit a yellow colour – this does not affect efficacy
References	<p>Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 23rd ed. Hudson (Ohio): Lexicomp; 2401.</p> <p>MIMS Australia. Linezolid In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2019 [cited 2019 May 1]. Available from: https://www.mimsonline.com.au</p> <p>Truven Health Analytics. Linezolid. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 May1]. Available from: https://neofax.micromedexsolutions.com/</p> <p>Society of Hospital Pharmacists of Australia. Buprenorphine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 May 1]. Available from: http://aidh.hcn.com.au</p>

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	January 2001	Version:	3.1
Last reviewed:	May 2019	Next review date:	May 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	May 2019
Standards Applicable:	NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety;		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			

© Department of Health Western Australia 2018